BIRC2 and melanoma: Treatment of two melanoma cell lines (Me13 and Me41) with the AZD6244–BEZ235–TRAIL combination induced strong downmodulation of c-IAP1, c-IAP2, XIAP and Apollon compared with the effects of single agents and to AZD6244–BEZ235 treatment (Figure 5a).